fbpx
LifestyleHealthNew Single-Dose Therapy Shows Promise Against Breast Cancer

New Single-Dose Therapy Shows Promise Against Breast Cancer

Researchers have developed a groundbreaking single-dose treatment that could transform the fight against breast cancer.

Advertisement

Breast cancer is one of the leading causes of cancer-related death in women.

But new treatment research has shown flimmers of hope of reversing that trend.

MORE GOOD NEWS: Mom Diagnosed with Cancer During Pregnancy Celebrates Daughter’s First Birthday Cancer-Free

The new treatment works by eliminating small tumors and significantly shrinking large ones without the severe side effects of current therapies.

Advertisement

Currently, breast cancer treatment involves surgery and several years of hormone therapy, which has several adverse late effects, including osteoporosis, sexual dysfunction and blood clots.

But the new compound, ErSO-TFPy, selectively targets estrogen receptor-positive (ER+) breast cancer cells and has shown remarkable results in preclinical studies.

Lead researcher Paul Hergenrother told the American Chemical Society: “It is very rare for a compound to shrink tumors in mouse models of breast cancer, let alone completely eradicate those tumors with a single dose, so we are eager for ErSO-TFPy to advance for treatment of breast cancer,” said lead researcher Paul Hergenrother.


Recommended Videos

Advertisement

In experiments, a single dose of ErSO-TFPy led to complete or near-complete regression of small and large tumors in mice.

The compound builds on earlier research into a molecule called ErSO, which killed ER+ breast cancer cells but caused undesirable side effects.

ErSO-TFPy, developed as a more potent and selective derivative, has demonstrated higher efficacy and better pharmacological properties.

MORE GOOD NEWS: Woman Finds Out She’s Cancer-Free After More Than 400 Days

While further studies are needed to confirm its safety and efficacy in humans, researchers believe ErSO-TFPy could be a transformative treatment for ER+ breast cancer.

Advertisement

The findings, published in ACS Central Science, highlight the potential of this single-dose therapy to address a major unmet need in breast cancer treatment. “The possibility of eradicating tumors with just one dose is a remarkable step forward in cancer treatment,” Hergenrother added.

Join our community of more than 500,000 Happily followers.

Advertisement

Editor's Picks

Advertisement
Advertisement

More good news

Embedded Style Sheet